Nyxoah ($NYXH): Can Genio Convert Clinical Progress into U.S. Sales?

01 Scenarios: commercial conversion is the central test

Nyxoah has crossed the initial regulatory threshold and is now being tested as a commercial business. Genio received FDA approval on August 8, 2025, and the company reported €14.047 million of revenue for the first half ended June 30, 2026. The next question is whether physician training and patient referrals can produce enough repeat business to support an expensive U.S. launch. The ACCCESS results provide a potential route into an additional patient group; the PMA supplement submitted on October 15 now awaits FDA review, and the expansion is not yet approved. Source Source Source

Bull case — adoption improves faster than the spending base

The favorable scenario requires sustained U.S. revenue growth, improved conversion of patients into implants and sufficient gross profit to narrow the operating deficit. September 21 guidance called for €36–40 million of worldwide revenue in 2026 (lowered on October 19 to €33–35 million), compared with €14.047 million already reported in the first half. A convincing second half would support the commercial thesis while ACCCESS advances through the regulatory process. Those outcomes are conditions for the scenario, not results already achieved. Source Source Source

An experienced U.S. medtech leader could help make the sales organization more productive. Liam Kelly became CEO on October 1, 2026, following the September 28 announcement. The useful evidence will be revenue from existing accounts, patient throughput and spending discipline under his leadership. A change of executive by itself does not show a better sales trajectory. Source

Base case — progress continues, but financing still matters

The middle scenario is a growing launch that continues consuming substantial cash. First-half operating cash use was €38.129 million through June 30, 2026, while cash and financial assets totaled €97.785 million at that date. The financing completed during the quarter provided room to execute, but it did not make the business self-funding. Further clinical evidence and more active accounts would coexist with dilution from existing instruments and the need to manage financing carefully. Source

In this scenario, the October 15 ACCCESS presentation and PMA supplement submission strengthen the regulatory file without immediately changing U.S. labeling, which depends on the FDA’s review. The November financial report becomes the stronger test of execution because it connects the sales pipeline with recognized revenue and remaining liquidity. Source Source

Bear case — adoption lags while the capital base keeps expanding

The unfavorable scenario would involve slower conversion of authorized patients, spending that remains high relative to gross profit, and additional shares issued before commercial scale improves. The company reported 101,840,217 ordinary shares on August 25, 2026, after another bond-related issuance. Existing convertible obligations mean that preserving cash can still increase the share count. A stronger balance sheet after an offering does not prevent dilution from weakening the outcome for each existing share. Source

Regulatory delay in CCC, weaker long-term safety or an adverse development in the patent dispute would compound that pressure. These are distinct risks: the commercial business can disappoint without a clinical failure, and successful clinical evidence does not guarantee an attractive financing outcome. Source Source Source

What Would Falsify This Reading

The constructive interpretation needs adoption, clinical evidence and financing to reinforce one another. These developments would weaken it.

• The sales funnel does not convert. Account growth and authorization activity fail to produce corresponding recognized revenue, undermining the productivity of the commercial build-out described in August. Source
• Cash consumption outruns progress. Operating cash use remains elevated while gross profit fails to improve, leaving less time to establish the model after the June financing. Source
• The CCC regulatory path weakens. FDA questions or requirements during review of the October 15 PMA supplement reduce the relevance of the ACCCESS result or delay the path to a broader U.S. indication. Source
• Dilution dominates the operating gains. Bond settlement and further funding increase shares faster than the underlying business improves. The August notice illustrates that sensitivity to settlement prices. Source

These are observations that would weaken the interpretation, not forecasts of inevitable events.

02 What Nyxoah sells and where the differentiation sits

Nyxoah is a Belgian medical technology company listed on Nasdaq and Euronext Brussels under NYXH. Its financial statements are in euros. The Nasdaq reference price of US$1.33 is the October 1, 2026 close; comparing it directly with euro-denominated debt or cash requires a stated exchange rate. Source Source

Genio stimulates both hypoglossal nerves to help keep the upper airway open during sleep. Its implanted component is leadless and battery-free, with power supplied by an external wearable component. That design differentiates the product, while adoption still requires a patient to accept surgery, use the system and remain within an appropriate treatment pathway. Source

The FDA’s August 2025 indication covers a defined adult population with moderate to severe obstructive sleep apnea that has failed, cannot tolerate or is ineligible for standard treatment. Approval therefore does not turn every person with sleep apnea into a prospective implant recipient. Clinical suitability, referral behavior, insurance authorization and operating-room capacity all narrow the path to a completed procedure. Source

This makes the commercial funnel more informative than a broad market-size estimate. A trained surgeon can be an early sign of readiness, but training does not show procedure frequency. An active account can begin ordering without immediately becoming a large recurring customer. A patient entering insurance review may still face scheduling and treatment decisions before revenue follows. These stages should be evaluated as related milestones rather than interchangeable measures of demand.

The company’s first-half report also distinguishes implant revenue from obligations for components supplied later. At June 30, 2026, current and noncurrent contract liabilities totaled approximately €1.722 million. Some consideration is recognized as those future obligations are satisfied. That timing is another reason to assess reported sales and cash collection alongside implant activity, rather than infer that every operational milestone becomes immediate revenue. Source

03 U.S. launch: encouraging activity, unfinished conversion

Nyxoah’s July 7, 2026 update described proposed 2027 CMS payments for Genio procedure code C8011 of $35,414 in hospital outpatient settings, versus $31,526, and $31,722 in ambulatory surgery centers, versus $27,563. The company characterized the increases as 12% and 15%. These were proposed facility reimbursement rates, not finalized payments or the price Nyxoah would receive per implant. Nyxoah preliminary second-quarter 2026 results release.

In its August 5, 2026 results release, Nyxoah reported 180 active high-volume U.S. accounts and 262 trained surgeons following the second quarter. There were 427 patients in active prior authorization entering the third quarter, a company-reported increase of 77% from the comparable pipeline entering the second quarter. These are useful leading indicators, with a clear distinction between physicians trained, accounts activated and patients progressing toward treatment. Source

U.S. revenue for the quarter ended June 30, 2026 was €5.197 million, compared with a calculated €4.254 million in the first quarter from the half-year total. The resulting sequential increase was about 22%, consistent with management’s release. The commercial launch is consequently producing recognized revenue, not merely a growing list of interested physicians. Source Source

The next report needs to show how much of the patient pipeline advances into procedures and how productive the account base becomes. Strong additions to the account count alongside weak revenue conversion would suggest that implementation is taking longer or requiring more support than the headline account growth implies. Conversely, more procedures within already activated accounts would make the sales organization more productive without requiring the same rate of new-account spending.

The August release reported a 100% approval rate on reviewed prior-authorization submissions. The relevant denominator is the submissions that had been reviewed; it is not all possible patients, and it is not a guarantee of universal coverage or completed implants. For the business, reimbursement matters when it helps suitable patients move through an actual treatment pathway. Source

International revenue also contributes. Germany generated €2.615 million during the first half of 2026, while the United States generated €9.451 million in the same period. That mix places increasing weight on American execution. A strong European history can support clinical confidence, but the cost of creating a U.S. sales infrastructure must be justified by U.S. revenue and ultimately cash contribution. Source

04 ACCCESS: positive results, followed by a regulatory decision

Nyxoah’s September 2, 2026 ACCCESS announcement reported an AHI responder rate of 77.2% and an oxygen-desaturation responder rate of 87.7%, both with p<0.001 in the full analysis set of 47 patients. The study addressed complete concentric collapse of the soft palate, or CCC. The analysis included imputation for missing observations; the percentages are not simple raw fractions of patients with complete observations. Source

The same announcement reported zero device-related serious adverse events through the twelve-month assessment. That is a specific safety finding, not a statement that no adverse events of any kind occurred. The full twelve-month dataset was presented at the International Surgical Sleep Society meeting in Los Angeles on October 15, 2026. In the per-protocol population, mean AHI fell from 33.6 to 10.4 events per hour, a median reduction of 74.3%, and mean ODI fell from 32.6 to 10.9, a median reduction of 71.9%, both p<0.001. The company reported no device- or procedure-related serious adverse events through 12 months; four unrelated SAEs gave an overall SAE rate of 7.5%. Patients will continue to be followed for three years after implant. Source

The clinical and regulatory implications must be separated. On October 15, 2026 Nyxoah said it had submitted a PMA supplement to the FDA to expand the U.S. indication to CCC patients. A submission is not an approval, and the company did not disclose an FDA review timeline. Existing U.S. labeling includes a warning concerning this population, whereas the company already has a European indication encompassing CCC. Geography and label status are therefore essential to interpreting the opportunity. Source Source

For a trader, the full dataset confirmed the September responder rates and added per-protocol detail; the open question now is how the FDA assesses the submitted supplement. The result to watch is consistent benefit accompanied by an interpretable safety profile. The submission date is not an FDA action date, and a positive statistical result does not fix how quickly an expanded indication could produce commercial revenue.

The possible advantage is a broader addressable treatment population and a more differentiated proposition for clinicians. The limitation is that this remains contingent on regulatory acceptance and subsequent commercial execution. Comparing the response rate directly with another company’s separate trial would introduce differences in populations and analysis that the headline percentages alone cannot resolve.

05 DREAM and BREATHE: established evidence and the durability test

The peer-reviewed DREAM report, published online in July 2025, provides the core clinical context. The intent-to-treat analysis reported AHI responses in 73 of 115 participants, or 63.5% with p=0.002, and oxygen-desaturation responses in 82 of 115, or 71.3% with p<0.001. The paper reported successful implantation in 113 participants and completion of the coprimary assessments by 89. Those denominators describe different populations and are not interchangeable. Source

The same publication reported eleven serious adverse events in ten participants, or 8.7%. The evidence supported the regulatory assessment, but the study was not a randomized head-to-head demonstration that Genio outperforms another implant. The useful conclusion is that there is a published clinical foundation for the approved device; it does not eliminate variation in response or the demands of longer follow-up. Source Source

On September 7, 2026, Nyxoah announced the first implantation in BREATHE, its U.S. post-approval study. The announced plan allows up to 229 patients with follow-up extending up to five years. The first implant shows that the study has begun; it does not provide a new efficacy result or mean the planned population has already been enrolled. Source

For the commercial thesis, longer-term evidence matters because treatment is an ongoing patient experience after surgery. Continued benefit, tolerability and consistent use influence physician confidence and the willingness of payers to support treatment. Any long-term concerns could affect both the installed patient base and the ease of recruiting future patients.

The two datasets answer different questions. DREAM underpins the initial approval. BREATHE is intended to broaden the evidence from routine U.S. practice. ACCCESS addresses an additional anatomical population. Treating them as successive versions of a single imminent readout would obscure the separate commercial and regulatory implications of each program.

06 Revenue guidance: the second half must do more work

Worldwide revenue was €7.675 million in the quarter ended June 30, 2026 and €14.047 million in the first half. September 21 guidance reaffirmed a full-year revenue range of €36–40 million; on October 19 the company lowered it to €33–35 million. Subtracting the first-half result from the new range implies €18.953–20.953 million of second-half revenue, or an average of approximately €9.477–10.477 million per quarter. These are calculated requirements to meet the annual range, not quarterly guidance from management. Source Source

The comparison is useful because the company must grow beyond the latest reported quarterly revenue level to deliver the annual forecast. The issue is not simply whether sales rise from a small prior-year base. It is whether the launch can sustain sequential progress while the organization spends to activate and support more treatment centers.

Gross profit in the second quarter of 2026 was €4.584 million on €7.675 million of sales, equivalent to a calculated margin of about 59.7%. Management reaffirmed a full-year gross-margin range of 60–62% on September 21. The August results discussion identified U.S. revenue mix and earlier production-yield issues as influences on margins. Higher sales therefore need to be assessed together with the cost of delivering the product. Source Source Source

The operating gap remains wide. The second-quarter operating loss was €20.588 million despite the increased revenue, and first-half selling, general and administrative expenses reached €30.992 million. A commercial infrastructure can require investment ahead of sales, but the economic test is whether that investment eventually produces enough gross profit to reduce losses. Source

Management’s reaffirmed September forecast put full-year operating expenses at €99–102 million and non-GAAP cash operating expenses at €88–90 million. Cash operating expenses exclude designated noncash items; they are not the same measure as net cash used in operating activities. Revenue collections, inventory and other working-capital movements also influence actual cash consumption. Source

07 Cash, monthly burn and the runway calculation

At June 30, 2026, Nyxoah held €64.115 million of cash and cash equivalents plus €33.670 million of financial assets, for a combined €97.785 million. The financial assets are separate from immediately available bank cash, even though management combines them in its liquidity presentation. The balance already reflects the equity financing and EIB draw completed during the second quarter. Source

Net cash used in operating activities during the first half of 2026 was €38.129 million. Dividing by six gives a calculated average monthly operating burn of approximately €6.355 million. Adding €2.008 million of property and equipment purchases and €0.159 million of intangible-asset purchases gives €40.296 million of combined operating and investment outflow, or €6.716 million per month. Source

Dividing June liquidity by that broader monthly rate gives about 14.6 months of historical coverage measured from June 30. It is a static calculation, not management guidance and not a runway starting on this page’s October update date. Future sales collections, launch spending, financing costs and capital needs can change the consumption rate. Source

The August 5 interim report concluded that resources were sufficient for at least twelve months from authorization of those financial statements. That updated assessment followed substantial financing. It should not be replaced by an older runway estimate from before the June capital raise, nor should the historical coverage calculation be converted into an exact date when cash supposedly runs out. Source

The balance-sheet improvement bought execution time at a substantial cost in new shares. A useful next-quarter assessment asks whether liquidity declines in line with operational progress: more sales and better gross profit could make spending more productive, while a similar cash decline with little commercial progress would shorten the time available to demonstrate the model.

The first-half net loss of €48.910 million is not the cash-burn numerator. It includes financial valuation effects and other noncash items. Using that loss as though every euro had left the bank would mix accounting volatility with the operating cash requirement. Source

08 Debt and financing capacity: three different obligations

The June 30, 2026 balance sheet reported €58.111 million of current and noncurrent financial debt. That is an accounting carrying amount spanning different obligations, including recoverable advances, EIB financing and convertible bonds. It is not a single face-value loan repayable on one date. Source

Under the EIB facility, the company drew €10 million in July 2024 and €13.75 million in June 2026. The first tranche carries annual interest of 5% in cash plus 5% capitalized; the second carries 4% in cash plus 4% capitalized. Each has a five-year bullet structure. A further €13.75 million tranche is conditional funding, not part of June’s received cash. The interim report says these tranches do not contain revenue or liquidity covenants, while disbursements remain subject to conditions. Source

The EIB synthetic warrants are cash-settled instruments. Their value can create a future cash obligation; they are not ordinary subscription warrants that automatically add the same number of shares to the capital base. This distinction matters when comparing debt economics with shareholder dilution. Source

The convertible bonds follow another mechanism. The first tranche was originally €22.5 million, bears a 6.5% annual coupon and matures in November 2028, with quarterly amortization. The August 25 notice reported remaining nominal principal of €16.7625 million across 225 bonds. Installments can generate new shares, as the August issuance demonstrates. Source Source

The June 4, 2026 capital update also described the March 2025 shelf registration of up to US$200 million, inclusive of an ATM program of up to US$50 million through Cantor. These are financing frameworks, not cash balances or a promise that the original full amounts remain available after subsequent transactions. Any use of the equity channel exchanges additional liquidity for more shares. Source

The practical question is how much funding the company needs before the sales organization becomes more efficient, and which mix of cash repayment, equity settlement and new issuance it uses. The absence of a revenue covenant on the EIB tranches does not remove the payment, delivery and other obligations under the separate convertible financing. Source Source

09 Share dilution: the denominator has already changed

Ordinary shares increased from 43,026,460 at December 31, 2025 to 100,072,815 at June 30, 2026. The June offering accounted for 55,232,558 new shares, while bond conversions and share-based awards contributed to the change. The half-year cash-flow statement reported approximately €76.041 million of net proceeds from issuing shares, already included in June liquidity. Source

The August 25, 2026 capital notice then reported 101,840,217 shares after 1,767,402 new shares were issued on August 20 in settlement of a bondholder receivable. This is the company denominator used here. The financing helped protect the operating plan but materially changed the interest represented by each previously existing share. Source

That notice also illustrated the bond’s sensitivity to settlement terms: principal conversion represented 11,326,013 shares at €1.48, compared with 13,410,000 shares using the rounded €1.25 relevant settlement price from August 18. Both figures excluded interest. These are dated alternatives, not additive obligations and not a fixed forecast of the ultimate dilution. Source

Subscription rights create a separate layer. The August notice identified 3,719,384 granted subscription rights at July 31, excluding 1,036,125 issued but ungranted rights. The June financial report separately disclosed repricing of outstanding incentive warrants to €1.53 and 358,267 RSUs granted to directors. These categories cannot simply be combined into a single common-share count. Source Source

Granting an award is different from an executive buying shares with personal cash. Likewise, authorized issuance capacity is different from an issued security. For an investor assessing dilution, the useful sequence is granted instruments, their exercise or settlement conditions, actual new issuance and the cash or obligation reduction received in return.

10 Ownership, insider activity and the short-interest snapshot

Finviz data as of October 2, 2026 showed a float of 81.29 million shares, short interest of 0.33% of float and a short ratio of 0.91. The underlying short-interest settlement date is not stated. These are dated third-party figures, not a same-day reconstruction of exchange short positions. The third-party figure of 100.07 million shares outstanding also trails the company’s August capital notice. Source Source

The same data showed insider ownership of 20.18% and institutional ownership of 23.68%. Classification and reporting dates affect those aggregates. They are not a perfectly synchronized register and cannot be added to convertible beneficial-ownership figures that include shares issuable in the future. Source

A primary June 17 transparency notice reported that chairman Robert Taub and Robelga held 14,440,277 voting shares following an acquisition on June 10, representing 14.45% at that notice’s denominator. This is evidence of increased ownership, not evidence that the shares were bought in open-market trading. The same notice showed Cochlear’s 5,847,283 shares and a passive reduction in its ownership percentage after the capital increase. Source

CVI and Heights reported 11,014,861 beneficially owned shares in their August 14 filing relating to June 30, 2026. That total included just 828,803 ordinary shares already held plus shares issuable under convertible notes, subject to the ownership blocker. Treating the whole beneficial total as a conventional institutional cash-equity position would overstate the number of existing shares held. Source

The reported short percentage is modest, so the stronger fundamental drivers are clinical interpretation, commercial execution and capital terms. A low reported short figure does not protect the price from a negative surprise, just as a large shareholder’s participation does not show that a new investor faces the same entry price or financing rights.

11 Red flags: commercial economics, patents and transition risk

The 2024 annual report also discloses a Man & Science collaboration effective October 1, 2024 to develop a miniaturized injectable neuromodulation device, with Nyxoah contributing research, clinical and regulatory expertise and retaining exclusive rights for obstructive sleep apnea. The September 2024 board resolutions identify financial conflicts involving Robert Taub, Jürgen Hambrecht and Olivier Taelman through their interests in Man & Science, and state that the conflicted directors did not vote on the relevant resolutions. This is a disclosed related-party governance consideration, not evidence of misconduct. Nyxoah 2024 annual report (PDF).

The most immediate risk is that the revenue ramp remains too small relative to the cost base. First-half operating cash consumption and the second-half revenue requirement make that tension measurable. A growing patient pipeline is encouraging, but the valuation ultimately depends on conversion into profitable treatment activity and a manageable need for further capital. Source Source

Patent litigation adds a separate uncertainty. The June 4 update described the consolidation of the U.S. cases with Inspire and the denial of institution of Nyxoah’s inter partes review petitions. The June interim report continued to describe the litigation and said the company could not quantify a potential loss. The absence of a recorded litigation-loss provision is therefore not a finding that the dispute is harmless or resolved. Source Source

Clinical success also does not eliminate competition from established implants and other sleep-apnea treatments. The annual report identifies that competition as a risk. Genio must earn physician confidence and patient acceptance while meeting its own post-approval obligations; technical differentiation alone does not determine market share. Source Source

Leadership is changing during the launch. Liam Kelly’s CEO appointment took effect October 1, while Loïc Moreau became interim CFO effective October 2 following John Landry’s departure. The relevant test is continuity in financial reporting, guidance and operating execution, rather than assuming either that the changes fix the business or that they necessarily signal an undisclosed problem. Source Source

12 What to watch and the Merlintrader bottom line

The full ACCCESS dataset was presented at ISSS on October 15, 2026, and the CCC PMA supplement was submitted to the FDA the same day, with no disclosed review timeline. The next scheduled financial checkpoint is November 5, 2026 for third-quarter results. The regulatory review will decide the CCC indication; the quarterly report should show revenue conversion, margins, spending, cash and changes in the capital base. They answer different questions and should be assessed separately. Source Source

For the commercial update, the clearest comparison is recognized U.S. sales against the account and prior-authorization indicators already disclosed. For liquidity, operating cash use matters more than the net-loss headline. For dilution, the issued-share denominator and actual bond settlement terms matter more than the rounded share counts shown by data services. Source Source Source

Nyxoah has an approved product, early U.S. revenue and positive evidence for a possible additional indication. It also has a substantial spending requirement and a capital structure that has already diluted existing holders significantly. The business case strengthens if the new management team turns clinical differentiation into repeat procedures and improving cash economics. It weakens if revenue growth requires persistent financing on terms that overwhelm the benefit per share. That is the central decision framework, without assigning a price target or recommending a trade.